A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

NCT04515147 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

668

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus
Covid19
SARS-CoV-2
Severe Acute Respiratory Syndrome

Interventions

BIOLOGICAL: CVnCoV 6 μg
BIOLOGICAL: CVnCoV 12 μg
BIOLOGICAL: Hepatitis A vaccine
BIOLOGICAL: Pneumococcal vaccine
BIOLOGICAL: CVnCoV 12μg

Sponsor

CureVac

Collaborators

[object Object]